This fact points to the sPLA2 family as a potential therapeutic target for atherosclerosis, and probably other diseases in which one or more sPLA2s are involved, such as asthma, arthritis, and metabolic syndrome. The gene discussed is PLA2G2A; the disease is arthritic joint disease.